Loading...
Loading...
PBYI| Name | Value |
|---|---|
| Revenues | 80.5M |
| Cost of Revenue | 29.1M |
| Gross Profit | 51.4M |
| Operating Expense | 29.4M |
| Operating I/L | 22.1M |
| Other Income/Expense | -1.5M |
| Interest Income | 1.3M |
| Pretax | 20.6M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | 20.3M |
Puma Biotechnology, Inc. is a biopharmaceutical company specializing in the development and commercialization of cancer care products. Its drug candidates include PB272 neratinib for early stage HER2-overexpressed/amplified breast cancer, as well as for advanced or metastatic HER2-positive breast cancer and HER2 mutation-positive solid tumors. The company generates revenue through the development and commercialization of these drug candidates, as well as through license and sub-license agreements with various pharmaceutical companies for the distribution and marketing of its products.
